LBA80 Siremadlin (S) and ribociclib (R) in patients (pt) with advanced well-differentiated/dedifferentiated liposarcomas (WD/DD LPS) and other molecularly selected cancers: Final analysis of the MEGAMOST "Ribociclib/HDM201" basket study.
Saved in:
| Title: | LBA80 Siremadlin (S) and ribociclib (R) in patients (pt) with advanced well-differentiated/dedifferentiated liposarcomas (WD/DD LPS) and other molecularly selected cancers: Final analysis of the MEGAMOST "Ribociclib/HDM201" basket study. |
|---|---|
| Authors: | Brahmi, M.1 (AUTHOR), Tredan, O.2 (AUTHOR), Gomez-Roca, C.A.3 (AUTHOR), Italiano, A.4 (AUTHOR), Saada, E.B.5 (AUTHOR), Bertucci, F.6 (AUTHOR), Le Cesne, A.7 (AUTHOR), Cassier, P.8 (AUTHOR), Treilleux, I.9 (AUTHOR), Chabaud, S.10 (AUTHOR), Fournier Garin, G.11 (AUTHOR), Perol, D.12 (AUTHOR), Blay, J-Y.13 (AUTHOR), Dufresne, A.14 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1266-S1266. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2024.08.2323 |
